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Abstract Megalencephalic leukoencephalopathy with
subcortical cysts (MLC) is a progressive cerebral white
matter disease with onset in childhood, caused by muta-
tions in the MLC1 gene. MLC1 is a protein with unknown
function that is mainly expressed in the brain in astrocytic
endfeet at the blood–brain and cerebrospinal Xuid–brain
barriers. It shares its localization at astrocytic endfeet with
the dystrophin-associated glycoprotein complex (DGC).
The objective of the present study was to investigate the
possible association of MLC1 with the DGC. To test this
hypothesis, (co)-localization of DGC-proteins and MLC1
was analyzed by immunohistochemical stainings in gliotic
brain tissue from a patient with multiple sclerosis, in glio-
blastoma tissue and in brain tissue from an MLC patient. In
control tissue, a direct protein interaction was tested by
immunoprecipitation. Results revealed that MLC1 is
co-localized with DGC-proteins in gliotic brain tissue. We
demonstrated that both MLC1 and aquaporin-4, a member
of the DGC, were redistributed in glioblastoma cells. In
MLC brain tissue, we showed absence of MLC1 and
altered expression of several DGC-proteins. We demon-
strated a direct protein interaction between MLC1 and
Kir4.1. From these results we conclude that MLC1 is asso-
ciated with the DGC at astrocytic endfeet.
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Introduction
Megalencephalic leukoencephalopathy with subcortical
cysts (MLC, MIM 604004) is a childhood leukoencephal-
opathy with autosomal recessive inheritance [21]. Patients
develop macrocephaly during the Wrst year of life, followed
by slow motor deterioration with cerebellar ataxia and spas-
ticity [21]. Magnetic resonance imaging (MRI) shows
diVusely abnormal, mildly swollen cerebral white matter
and subcortical cysts in anterior temporal and frontoparietal
areas [21]. Histopathologic and electron microscopic
examination of brain tissue reveals countless intramyelinic
vacuoles [22].
From early on, the striking similarity in MRI features of
MLC and congenital muscular dystrophy (CMD) with mer-
osin deWciency (CMD type 1A, MDC1A) was noted [21].
Patients with MDC1A also have diVusely abnormal, mildly
swollen cerebral white matter and sometimes anterior tem-
poral cysts (Fig. 1) [23]. Microscopic examination of the
brain of a patient, who was later genetically conWrmed to
have MDC1A (B. Echenne, personal communication) also
revealed myelin vacuolation [8]. MDC1A is caused by
mutations in the LAMA2 gene, encoding the laminin-2
chain of merosin [9]. In contrast to MDC1A, MLC is not
associated with muscle disease [21]. We hypothesized that
MLC could be the “brain-only” variant of MDC1A. We
could, however, not conWrm linkage of MLC to the LAMA2
locus and instead demonstrated that mutations in another
gene, MLC1, cause MLC [10]. MLC1 encodes a plasma-
membrane protein of unknown function. Recently, the
MLC1-protein was found to be located in astrocytic endfeet
at the blood–brain and cerebrospinal Xuid–brain barriers [3,
19].
Other proteins localized at astrocytic endfeet are those of
a multi-subunit complex called dystrophin-associated
glycoprotein complex (DGC) [12,  20]. The DGC is
expressed in various tissues and has been characterized best
in skeletal muscle where it connects the cytoskeleton of
muscle Wbers to the extracellular matrix [14]. Mutations in
diVerent DGC components lead to various muscular dystro-
phies. In a subset of muscular dystrophies, the congenital
muscular dystrophies (CMDs), the muscular phenotype is
often combined with brain involvement, including white
matter abnormalities, most notably in MDC1A [23].
The brain DGC is involved in the adhesion of perivascu-
lar glia to the extracellular matrix [20]. At the astrocytic
endfeet, the DGC consists of four main components [6, 16,
29]: (1) - and -dystroglycan, which form the backbone of
the DGC by forming a transmembrane link between the
actin cytoskeleton and the extracellular matrix. -Dystro-
glycan is a heavily glycosylated peripheral membrane
protein that binds to extracellular ligands such as merosin
Fig. 1 MRI of the brain of a patient with MLC (a–c) and MDC1A
(d–f). The axial T2-weighted images (a, b, d, e) reveal extensive signal
abnormalities and mild swelling of the cerebral white matter in both
MLC (a, b) and MDC1A (d, e). The corpus callosum and internal
capsule are relatively preserved in both cases (a,  d). The sagittal
T1-weighted images reveal a large cyst in the anterior temporal white
matter and smaller cysts in the frontal subcortical white matter in the
MLC patient (c). There are small cysts in the same regions in the
MDC1A patient (f). Both MLC and MDC1A patients had a genetically
conWrmed diagnosisActa Neuropathol (2007) 114:403–410 405
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and agrin. -Dystroglycan is a transmembrane protein that
anchors the extracellular -dystroglycan to the plasma
membrane and interacts intracellularly with dystrophin
(and/or utrophin, which can replace dystrophin) and syntro-
phin. (2) Dystrophin and/or utrophin, are linker molecules
that can form a bridge between actin and -dystroglycan.
(3) -Dystrobrevin, which is linked to dystrophin and/or
utrophin binds to syntrophin. (4) Syntrophin, which binds
to the water channel aquaporin-4 and the potassium channel
Kir4.1 is responsible for the polarized expression of these
proteins in astrocytic endfeet.
The striking similarities in brain MRI features and
pathology between MLC and MDC1A, together with the
speciWc localization of both MLC1 and merosin at astro-
cytic endfeet, brought us to the hypothesis that there may
be an association between MLC1 and DGC in the brain. In
the present paper we report on our studies to test this
hypothesis. We investigated the co-localization of MLC1
and DGC-proteins in gliotic white matter, because MLC1
staining is more intense in gliotic brain tissue than in nor-
mal tissue [3]. Previous studies in humans and mice have
shown that if members of the DGC are mutated or missing,
the complex may be disrupted, which aVects the localiza-
tion of other protein members [1, 13, 16, 27]. We therefore
also tested our hypothesis by studying the localization of
MLC1 and several DGC-proteins in glioblastoma and MLC
brain tissue. Besides, we assessed a direct association
between MLC1 and DGC-members by co-immunoprecipi-
tation experiments.
Materials and methods
Immunohistochemical staining of human brain tissue
Human control brain tissue specimens, both frozen and
paraYn-embedded, consisting of neocortex and white
matter, were obtained at autopsy from patients without neu-
rological disease and neuropathologic abnormalities. Addi-
tionally, frozen brain tissue was obtained from a multiple
sclerosis patient to study gliotic white matter in which
MLC1 has a normal localization but MLC1 expression is
increased [3]. During life, all patients or their next of kin
had given consent for autopsy and the use of brain tissue for
research purposes.
Human glioblastoma multiforme tissue (frozen) and
brain biopsy tissue from MLC patients (both frozen and
paraYn-embedded) were obtained for diagnostic purposes
and used for research purposes with informed consent of
patients and families. Light-microscopy of glioblastoma tis-
sue was used to select areas that display characteristic glio-
blastoma features, including necrosis, giant cells and
endothelial proliferation, for further studies. Brain biopsies
were obtained in the following MLC patients: EL18
(decreased MLC1 expression [2], frozen tissue), EL649
(homozygous for the c.733G > C (p.Ala245Pro) mutation;
paraYn-embedded tissue), and EL746 [compound-hetero-
zygous for the c.268-1G > A and c.597 + 1G > A muta-
tions, leading to splice-defects and truncation of the protein
(p.Cys90-Val107del and p.Val200-Ala238del); paraYn-
embedded tissue].
Immunohistochemistry was performed as described pre-
viously [7] with antibodies against the following proteins:
MLC1 (polyclonal; 1:200 [3]); merosin (monoclonal; 1:500
[11]); aquaporin-4 (polyclonal; 1:200, Chemicon, Huissen,
The Netherlands); Kir4.1 (polyclonal; 1:200, USBiological,
Swampscott, Massachusetts), -dystroglycan (monoclonal;
1:100, Santa Cruz, Heidelberg, Germany), -dystroglycan
(monoclonal; 1:100, UpstateCellSignaling solutions), agrin
(monoclonal; 1:2500 [26]); glial Wbrillary acidic protein
(GFAP, polyclonal; 1:500, DAKO, Heverlee, Belgium) and
NeuN (monoclonal; 1:1600, MAB377, Chemicon). In all
slides, except the slides used for double stainings, the
nuclei are counterstained with Haematoxylin. Double
immunoXuorescence staining was performed as described
[3] with agrin, -dystroglycan (monoclonal; 1:100) or syn-
trophin (monoclonal; 1:100, AYnity BioReagents,
Raamdonksveer, The Netherlands) versus MLC1. In nega-
tive controls the primary antibodies were omitted. Double-
stainings were performed as described previously [25]. In
frozen tissue double-stainings were done with agrin (red)
antibodies versus AB4 (blue, polyclonal; 1:200, Lab
Vision–NeoMarkers, Fremont, CA, USA) antibodies and in
paraYn tissue with agrin or -dystroglycan antibodies ver-
sus NeuN or GFAP. For the agrin (brown)/NeuN (blue)
double-stainings, agrin was visualized with biotinylated
secondary antibodies (DAKO) and NeuN with poly-HRP
(Immunologic, Duiven, The Netherlands). For the agrin
(red)/GFAP (blue) double-stainings, agrin was detected
with poly-HRP (Immunologic) and GFAP with biotinylated
secondary antibodies (DAKO). In negative controls the pri-
mary antibodies were omitted.
Immuno-precipitation and western blotting
Preparation of brain tissue and immunoprecipitation
experiments were performed as previously described [5]
without antibodies as a negative control, with 1–15 g
mMLC1-C (home made), with the nonspeciWc CHOP
(Santa Cruz, Heidelberg, Germany) as an extra negative
control, and with Kir4.1 (USBiological, Swampscott,
Massachusetts) antibodies. Western blots were incubated
with the Kir4.1 antibodies overnight at 4°C and
complexes were visualized using ECL Western Blot
detection reagents (Amersham, Buckinghamshire, United
Kingdom).406 Acta Neuropathol (2007) 114:403–410
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Results
Co-localization of MLC1 and DGC-members
To test whether MLC1 co-localizes with DGC-proteins at
astrocytic endfeet, we performed double-immunoXuores-
cent staining experiments in gliotic brain tissue with the
transmembrane protein MLC1 (Fig. 2a, d, g; green) versus
the extracellular matrix protein agrin (Fig. 2b; red), the
intracellular protein syntrophin (Fig. 2e; red), and the trans-
membrane protein -dystroglycan (Fig. 2h; red). There was
partial overlap (yellow) between all three DGC-proteins
(red) and MLC1 (green). The co-localization (Fig. 2i;
yellow) of MLC1 (Fig. 2g; green) and -dystroglycan
(Fig. 2h; red) was most striking. If MLC1, agrin, -dystro-
glycan or syntrophin was omitted, Xuorescent labeling was
only visible for the appropriate isotype, thereby excluding
cross-reactivity (not shown). On omission of the primary
antibody no staining was observed (not shown).
MLC1 and aquaporin-4 are redistributed in glioblastoma 
cells
Staining normal human brain tissue with anti-MLC1 and
anti-aquaporin-4 antibodies conWrmed their speciWc expres-
sion around blood vessels, consistent with the previously
described perivascular localization (Fig. 3a, c) [3, 15]. In
glioblastoma tissue, both MLC1 and aquaporin-4 had
altered expression patterns. The proteins were no longer
conWned to astrocytic endfeet, but were redistributed over
the entire glioblastoma cell (Fig. 3b, d). Anti-agrin staining
showed expression of the protein in the extracellular matrix
around blood vessels of all sizes in normal brain tissue
(Fig. 3e), whereas it was exclusively expressed around
larger blood vessels in glioblastoma tissue (Fig. 3f). Double
staining of agrin (red) with AB4 (blue), an endothelial
marker, in glioblastoma tissue conWrmed agrin and AB4
staining around larger blood vessels (Fig. 3g) and absence
of agrin around small vessels (Fig. 3g, boxed area). This is
in line with previously published results [27]. On omission
of the primary antibody no staining was observed (not
shown).
Absence of MLC1 and altered expression of DGC-proteins 
in MLC brain tissue
Anti-MLC1 staining revealed perivascular expression of
the protein in control brain tissue (Fig. 4a) [3] and absence
of staining in MLC tissue (Fig. 4b). The distribution of
merosin,  -dystroglycan and aquaporin-4 was similar in
Fig. 2 Co-localization of MLC1 and DGC-proteins. a–i Double
immuno-Xuorescence labelling of MLC1 (a,  d,  g,  green), agrin
(b, red), syntrophin (e, red), and -dystroglycan (h, red) in gliotic hu-
man brain tissue. There is partial overlap (c, f, i, yellow) between
MLC1 and these DGC-proteins. The overlap (i, yellow) between the
transmembrane proteins MLC1 (green) and -dystroglycan (red) is
most striking. In all panels the ocular magniWcation and 10 m scale
bars are indicated in the lower right hand cornerActa Neuropathol (2007) 114:403–410 407
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control (Fig. 4c, e, g) and MLC tissue (Fig. 4d, f, h). In
control tissue, Kir4.1 showed a perivascular localization in
conWguration suggesting presence in distal atroglial
processes (Fig. 4i), while in MLC patient tissue Kir4.1
additionally showed a diVuse cytoplasmic staining of
astrocytes (Fig. 4j). In control tissue, agrin (Fig. 4k) and
–dystroglycan (Fig. 4m) were seen in the perivascular
extracellular matrix, whereas these proteins were observed
both in the perivascular extracellular matrix and within
cells in MLC tissue (Fig. 4l, n).
The cells expressing these latter two DGC-proteins had
the morphological characteristics of neurons. Double stain-
ings of agrin and -dystroglycan with NeuN, a neuronal
marker, in MLC brain tissue conWrmed that both agrin
(brown) (Fig. 4o) and -dystroglycan (not shown) co-local-
ized with NeuN (blue). Although, most redistribution
appeared to be in neurons, double stainings of agrin (red)
and GFAP (blue) showed that also some astrocytes dis-
played positive cell body staining for agrin (Fig. 4p). On
omission of the primary antibody no staining was observed
(not shown).
Direct protein interaction between MLC1 and Kir4.1
To verify interaction of DGC-proteins with MLC1, immu-
noprecipitation experiments were performed using human
control brain lysates. Figure 5 shows that after immunopre-
cipitation with both anti-MLC1 and anti-Kir4.1 antibodies
and probing the precipitate for the presence of Kir4.1, a
band at 200 kDA was detected, the size expected for
Kir4.1. This band was not present in a pull-down without
antibodies or with an unrelated antibody (anti-CHOP). Of
concern in this experiment was the use of cross-linking
reagents, since this might cause nonspeciWc interactions.
When cross-linking reagents were left out, we failed to
detect interactions, which is in agreement with previous
studies on interaction between DGC-members [5].
Discussion
The DGC is important in linking cytoskeletal proteins to the
extracellular basal lamina. It is present in several tissues
including muscle, heart, nerve and brain. The composition of
this complex shows some diVerences for diVerent tissues.
Structural defects in a number of DGC-members cause
muscular dystrophies. Best known is Duchenne muscular
dystrophy, related to mutations in dystrophin. Another mus-
cular dystrophy is the CMD MDC1A, in which the MRI fea-
tures are strikingly similar to those of MLC. MDC1A is
caused by mutations in the laminin-2 chain of merosin [9].
A speciWc group of CMD variants is known as “dystrogly-
canopathies” and includes Walker–Warburg syndrome,
Fukuyama type of CMD, muscle–eye–brain disease, CMD
type 1C and type 1D. They are characterized by hypogly-
cosylation of -dystroglycan [14]. MDC1A and most of the
dystroglycanopathies lead to both muscle disease and brain
involvement, including cerebral white matter abnormalities.
Fig. 3 Localization of MLC1 in glioblastoma tissue. Immunohisto-
chemical staining of MLC1, aquaporin-4 (AQP4) and agrin in control
brain (a, c, e) and tumor tissue (b, d, f, g). a MLC1 has a perivascular
localization in normal tissue. b In glioblastoma tissue, the restriction of
MLC1 to perivascular areas is lost and the protein has an intracellular
location in glioblastoma cells. c AQP4 is expressed in perivascular as-
troglial endfeet in control brain. d AQP4 is localized in glioblastoma
cells. e, f Agrin is expressed in the extracellular matrix around blood
vessels of all sizes in normal tissue (e) and only around large vessels in
glioblastoma tissue (f). g Double-staining of agrin (red)/AB4 (blue) in
glioblastoma tissue shows agrin and AB4 (endothelial marker) staining
around larger blood vessels. The boxed area in panel g shows that agrin
staining is absent around small vessels. In all panels the ocular magni-
Wcation and 10 m scale bars are indicated in the lower right corner408 Acta Neuropathol (2007) 114:403–410
123
Fig. 4 Localization of proteins associated with the DGC in MLC
patients. In control tissue the perivascular staining of MLC1 is visible
(a), but no staining is observed in MLC brain tissue (b). Normal
perivascular basal lamina staining with merosin is seen in control (c)
and MLC (d) brain tissue. -dystroglycan has a normal perivascular
distribution in both control (e) and MLC (f) brain tissue. Aquaporin-4
(AQP4) has a normal perivascular distribution in both control (g) and
MLC (h) brain tissue. Kir4.1 is present in distal astrocytic processes
around blood vessels in control tissue (i). In MLC tissue (j) Kir4.1 is
expressed both in distal astrocytic processes around blood vessels and
in cell bodies of astrocytes (boxed area). Agrin is expressed in the
extracellular matrix around blood vessels in control tissue (k). In MLC
tissue (l) agrin is expressed in both the extracellular matrix around
blood vessels (boxed area) and in cells, as indicated by arrows.
Immunostaining for –dystroglycan shows a normal perivascular dis-
tribution in control tissue (m) and expression of –dystroglycan
around blood vessels (boxed area) and in cells in MLC tissue (arrows
in n). o Double-staining of NeuN (blue)/agrin (brown) in MLC tissue
shows cytoplasmic agrin staining in NeuN positive cells (arrows).
p Double-staining of Agrin (red)/GFAP (blue) in MLC brain tissue.
The picture on the left shows an astrocyte that is only GFAP positive
(arrow), while the picture on the right shows an astrocyte that is both
GFAP and agrin positive (arrow, brown staining in cell body). In all
panels the ocular magniWcation, 10 m scale bars and patient numbers
are indicated in the lower right cornerActa Neuropathol (2007) 114:403–410 409
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We hypothesized that MLC1 could be associated with
the DGC in the brain. To strengthen our hypothesis, we
showed co-localization between MLC1 and DGC-proteins
around blood vessels by immunoXuorescent stainings. A
common feature of the DGC is that mutations aVecting one
of its components often lead to destabilization of the com-
plex with reduced or altered expression of other DGC-
members. For instance, in muscle and brain tissue of
patients with a dystroglycanopathy, immunostaining is
reduced for -dystroglycan as well as merosin and agrin
[13]. In patients with Duchenne muscular dystrophy and
Fukuyama type of CMD, decreased expression of multiple
DGC-proteins has been found in muscle and brain [4, 17,
18]. In brain tissue of syntrophin, knock out mice altered
expression of aquaporin-4 has been reported [16]. In glio-
blastoma tissue, abnormal expression of aquaporin-4 and
syntrophin over the entire surface of glioblastoma cells and
absence of -dystroglycan from glial structures have been
reported [27,  28]. Agrin was only present around larger
vessels but absent around small vessels in glioblastoma tis-
sue [27, 28]. We decided to use these DGC destabilization
phenomena to test our hypothesis. Because of the co-locali-
zation of MLC1 and DGC-members at perivascular regions
and the disassembly of the DGC in glioblastoma tissue we
were interested in whether MLC1 is redistributed in this
type of brain tumor. We, therefore, tested the expression
pattern of MLC1 by immunohistochemical staining in glio-
blastoma tissue. We conWrmed previous Wndings for agrin
and aquaporin-4 [27, 28] and demonstrated that MLC1, like
aquaporin-4, is redistributed in glioblastoma cells. We were
also interested whether MLC1 mutations would lead to
destabilization of the complex with reduced or altered
expression of DGC-members in MLC brain. We demon-
strated the absence of MLC1 and altered expression of
Kir4.1, agrin and -dystroglycan in brain tissue of MLC
patients, whereas merosin, -dystroglycan and aquaporin-4
retained their normal perivascular localization. Agrin and
-dystroglycan were redistributed in both neurons and
astrocytes, although most positive staining cells appeared to
be neurons. All the above results provide circumstantial
evidence for an association between MLC1 and the DGC.
To show a direct protein–protein interaction we performed
co-immunoprecipitation experiments that revealed an asso-
ciation between MLC1 and Kir4.1. All together, the above
Wndings provide strong evidence for an association between
MLC1 and the DGC.
So far almost all defects in DGC-proteins have been
associated with a muscular dystrophy, which is absent in
MLC. This diVerence can be ascribed to a diVerence in
DGC composition for muscle as compared to brain.
Whereas merosin is expressed both in muscle and brain,
MLC1 is not expressed in muscle (http://biomed.ngic.re.kr/
cgi-bin/cards/carddisp?MLC1&search = KIAA0027) Both
in MLC and MDC1A, the water content of the aVected
white matter is abnormally high due to intramyelinic vacu-
ole formation [8, 22, 24]. The DGC is crucial for anchoring
of water and potassium channels at the perivascular endfeet
[15]. Destabilization of the DGC may lead to changes in
glial polarity, disturbances of the blood–brain barrier and
alterations in ion and water homeostasis of the brain [27,
28], and result in an increased myelin water content. Our
Wndings may, therefore, have implications for the patho-
physiology of white matter abnormalities observed in
MLC, MDC1A and the dystroglycanopathies.
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